Werewolf Therapeutics announced its third‑quarter 2025 earnings today, reporting financial results for the quarter ended September 30, 2025. The company made the announcement in a business update issued from WATERTOWN, Mass., on November 4, 2025.
The update highlighted progress on its lead clinical programs, noting that WTX‑124 received Fast Track designation and that the company will provide a fourth‑quarter update on the path to a registration‑enabling trial. It also mentioned ongoing IND‑enabling studies for WTX‑1011 and plans to nominate a differentiated target candidate by year‑end.
Investors can find detailed financial figures and guidance on the company’s investor relations website. The announcement underscores Werewolf’s continued focus on advancing its PREDATOR platform and maintaining its cash runway into late 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.